Background
This blog provides summary on what is known about initial §137h NUB-related submission by Bioventrix, Holaira and Haifu.
There are many aspects that are changing with the introduction of the new 137h process to assess the benefit of the new innovations coming to market. We will provide more information about all of these changes in a webinar in a few weeks.
The Italian National HTA body (Agenas) recently published a report to evaluate the current national and regional regulation of patients’ co-payments for put-patient care.